A computer may soon be able to offer highly personalized treatment suggestions for cancer patients based on the specifics of their cases and the full sweep of the most relevant scientific research.
IBM and the New York Genome Center, a consortium of medical research institutions in New York City, are collaborating on a
project
The work, which got underway in 2013, is exploring the use of computers to help analyze a wide range of genetic information and the scientific literature with the goal of quickly formulating precise treatment plans for cancer patients.
The line of research is being orchestrated by
Robert Darnell
An essential assistant on Darnell's team is supercomputer
IBM Watson
Watson wasn't always part of Darnell's lineup. When he started the project, he relied on the collective brainpower of a bunch of medical researchers in New York City. Fifteen of them, including Darnell, spent three weeks evaluating the case of the first patient of the project. But, he says, "by the time we got through with this patient, the patient died."
Speed matters, given how fast cancer can spread. Information overload is a particular challenge.
"Cancer is not giving you the luxury of time," says
Ajay Royyuru
In contrast, IBM's supercomputer Watson, famous for defeating former champions in Jeopardy!
in 2011
Upon learning about Watson's abilities, Darnell approached IBM. By 2014, a human-computer coalition to fight cancer
was born
"Compare what the genetics in the healthy cell looks like to what the genetics in the cancer cell looks like, you get the list of differences," says
Steve Harvey
With the help of Watson, Darnell's group studied 30 patients with glioblastoma, an aggressive form of brain cancer, and developed personalized treatment options for each patient "based on genetic mutations present in the tumor," according to Darnell. Darnell declined to comment on the specifics of the findings before they're published. But, he says, "there are patients who will benefit" from this study. A preliminary report on the findings has been submitted to The Journal of Clinical Oncology.
Both IBM and the New York Genome Center are moving on to find out whether Watson can apply what he learned from Darnell's research to a larger group of glioblastoma patients.
"We'll be
working with
According to Darnell, the paper his group submitted will "lay the groundwork for the larger, more comprehensive paper on the same study." Darnell says the current research project is not yet a clinical trial, and he hopes to execute a large-scale clinical trial in the future, recruiting "any cancer patient who is sick, not necessarily from glioblastoma."
Copyright 2016 NPR. To see more, visit
http://www.npr.org/